1 / 9

Grand Challenges for Nanomedicine and Nanobiology Workshop Houston, Texas August 27 th , 2007

Grand Challenges for Nanomedicine and Nanobiology Workshop Houston, Texas August 27 th , 2007. Personal Thoughts. Targeted Delivery (Timing) EPR Tumor vasculature Potential for clinical impact versus clinical translation Diagnostics and Nanotechnology? Training and Team Science

takoda
Télécharger la présentation

Grand Challenges for Nanomedicine and Nanobiology Workshop Houston, Texas August 27 th , 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Grand Challenges for Nanomedicine and Nanobiology Workshop Houston, Texas August 27th, 2007

  2. Personal Thoughts • Targeted Delivery (Timing) • EPR • Tumor vasculature • Potential for clinical impact versus clinical translation • Diagnostics and Nanotechnology? • Training and Team Science • Multi-PI R01s • NIH Pathway to Independence Award (K99/R00) • Mentored Research Scientist Development Award (K01) • Mentored Clinical Scientist Development Award (K08) • Clinical Oncology Training Grants (K12)

  3. Upcoming Sessions Nano Tutorial Sessions: Oct 16th, 2007 • Tutorial Session 1: Cells, Tissues, and Organs: Basic Principles of Functional Histology and Pathology • Tutorial Session 2: Basic Cancer Biology • Tutorial Session 3: Animal Models • Tutorial Session 4: Biodistribution of Nanoparticles • Tutorial Session 5: Materials Science/Nanotechnology • Clinical Pathway • Clinical trial grants and contracts • FDA • Nanotechnology Characterization Lab ASCB Special Session: Dec 1st, 2007

  4. Upcoming NIH Funding Opportunities • Nanoscience and Nanotechnology in Biology and Medicine (R01&R21), Oct. 22nd, 2007 • Biology of Breast Pre-Malignancies (R01), Nov. 17th, 2007 • RFA-CA-07-047 • insufficient understanding of normal and pre-cancer biology

  5. Upcoming NCI Funding Opportunities • SBIR Solicitation (PHS-2008-1), Nov. 5th, 2007 • Topic 241: Multifunctional Therapeutics Based on Nanotechnology • Topic 252: Nanotechnology Imaging and Sensing Platforms for Improved Diagnosis of Cancer • Multidisciplinary Development and Training in Cancer Nanotechnology Award (F32/F33), TBA • Innovative Molecular Analysis Technologies [IMAT] (R21/R33), Sept. 27th, 2007 • Innovative Technologies for the Molecular Analysis of Cancer: RFA-CA-07-033 • Application of Emerging Technologies for Cancer Research: RFA-CA-07-035 nano.cancer.gov

  6. Nanotechnology Characterization Lab (NCL)Role and Updates In Vitro In Vivo Physicochemical • The NCL developed and standardized analytical cascade that tests the pre-clinical toxicology, pharmacology, and efficacy of nanoparticles and devices. • Next submission date (9/1/2007 and 12/1/2007)

  7. NCL in vivoCharacterization Assays Plasma Profile • Initial disposition study • Tissue Distribution • Clearance • Half-life • Systemic exposure (plasma AUC)   • Immunotoxicity • 28 day screen • Immunogenicity (repeat-dose tox study)    • Dose -Range Finding Toxicity • Blood Chemistry • Hematology • Histopathology • Gross Pathology • GLP Studies • PK/ADME • Expanded Single Dose Acute Tox Organ Weights Main Study Hematology Interim Study

  8. Current NCL Collaborators

  9. Onsite Program Contacts • Larry Nagahara, Ph.D.Nanotechnology Projects Manager • Email:  nagaharl@mail.nih.gov • Jerry Lee, Ph.D. • Tech. Dev. Program Officer • Email: leejerry@mail.nih.gov

More Related